Aficamten improved outcomes for patients with obstructive hypertrophic cardiomyopathy: Phase 3 SEQUOIA-HCM trial
USA: The pivotal Phase 3 clinical trial (SEQUOIA-HCM) of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) has yielded positive results, as announced by drugmaker Cytokinetics. The top-line results from the SEQUOIA-HCM trial showed that aficamten, a novel cardiac myosin inhibitor, improved outcomes for patients with symptomatic obstructive HCM. The full results from SEQUOIA-HCM […]